Thermogenic drugs as a strategy for treatment of obesity (Q34143869)

31 July 2017

1 reference

title

Thermogenic drugs as a strategy for treatment of obesity (English)

1 reference

31 July 2017

0 references

Astrup A

1

1 reference

31 July 2017

1 October 2000

1 reference

31 July 2017

1 reference

31 July 2017

13

1 reference

31 July 2017

2

1 reference

31 July 2017

207-212

1 reference

https://scigraph.springernature.com/pub.10.1385/endo:13:2:207

31 July 2017

0 references

cites work

A double-blind randomized placebo-controlled trial of sibutramine

1 reference

12 December 2020

The effect of ephedrine/caffeine mixture on energy expenditure and body composition in obese women

1 reference

12 December 2020

Total energy expenditure and the level of physical activity correlate with plasma leptin concentrations in five-year-old children

1 reference

12 December 2020

Meta-analysis of resting metabolic rate in formerly obese subjects

1 reference

12 December 2020

Sibutramine and thermogenesis in humans

1 reference

12 December 2020

Human beta-2 adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered adipocyte beta-2 adrenoceptor function

1 reference

12 December 2020

The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial

1 reference

12 December 2020

Evidence for a functional beta 3-adrenoceptor in man.

1 reference

12 December 2020

Sibutramine reduces food intake in non-dieting women with obesity

1 reference

12 December 2020

The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction

1 reference

12 December 2020

Sibutramine: a review of the pharmacology of a novel anti-obesity agent

1 reference

12 December 2020

Thermogenic effects of sibutramine in humans

1 reference

12 December 2020

Determinants of 24-hour energy expenditure in man. Methods and results using a respiratory chamber

1 reference

12 December 2020

The sympathetic nervous system and obesity: role in aetiology and treatment

1 reference

12 December 2020

Thermogenic, metabolic, and cardiovascular responses to ephedrine and caffeine in man

1 reference

12 December 2020

The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females

1 reference

12 December 2020

Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass

1 reference

12 December 2020

Effects of the two beta3-agonists, ZD7114 and ZD2079 on 24 hour energy expenditure and respiratory quotient in obese subjects

1 reference

12 December 2020

Macronutrient balances and obesity: the role of diet and physical activity.

1 reference

12 December 2020

Fat metabolism in formerly obese women

1 reference

12 December 2020

Congenital leptin deficiency is associated with severe early-onset obesity in humans

1 reference

12 December 2020

Safety and efficacy of long-term treatment with ephedrine, caffeine and an ephedrine/caffeine mixture

1 reference

12 December 2020

Energy expenditure, body composition, and glucose metabolism in lean and obese rhesus monkeys treated with ephedrine and caffeine.

1 reference

12 December 2020

Prospects for beta 3-adrenoceptor agonists in the treatment of obesity and diabetes

1 reference

12 December 2020

Norepinephrine turnover and energy expenditure in Pima Indian and white men

1 reference

12 December 2020

Thermogenesis in human brown adipose tissue and skeletal muscle induced by sympathomimetic stimulation

1 reference

12 December 2020

Contribution of beta 3-adrenoceptor activation to ephedrine-induced thermogenesis in humans

1 reference

12 December 2020

Twenty-four-hour energy expenditure: the role of body composition, thyroid status, sympathetic activity, and family membership.

1 reference

12 December 2020

Effects of mutations in the human uncoupling protein 3 gene on the respiratory quotient and fat oxidation in severe obesity and type 2 diabetes

1 reference

12 December 2020

Overexpression of muscle uncoupling protein 2 content in human obesity associates with reduced skeletal muscle lipid utilization.

1 reference

12 December 2020

Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective beta3-adrenoceptor agonist in humans

1 reference

12 December 2020

Effects of recombinant leptin therapy in a child with congenital leptin deficiency.

1 reference

12 December 2020

Development of beta 3-adrenoceptor agonists for the treatment of obesity and diabetes--an update.

1 reference

12 December 2020

The effect of ephedrine plus caffeine on plasma lipids and lipoproteins during a 4.2 MJ/day diet

1 reference

12 December 2020

Impact of the v/v 55 polymorphism of the uncoupling protein 2 gene on 24-h energy expenditure and substrate oxidation

1 reference

12 December 2020

Contribution of BAT and skeletal muscle to thermogenesis induced by ephedrine in man

1 reference

12 December 2020

Skeletal muscle UCP2 and UCP3 expression in trained and untrained male subjects

1 reference

12 December 2020

Meta-analysis of the association of Trp64Arg polymorphism of beta 3-adrenergic receptor gene with body mass index.

1 reference

12 December 2020

Enhanced thermogenic responsiveness during chronic ephedrine treatment in man.

1 reference

12 December 2020

Effects of red pepper added to high-fat and high-carbohydrate meals on energy metabolism and substrate utilization in Japanese women

1 reference

12 December 2020

Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans

1 reference

12 December 2020

Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial

1 reference

12 December 2020

Identifiers

DOI

10.1385/ENDO:13:2:207

1 reference

PubMed ID

11186222

Dimensions Publication ID

31 July 2017

0 references

1 reference

PubMed ID

11186222